


QNZ

## Chemical Properties

CAS No. : 545380-34-5  
 Formula: C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O  
 Molecular Weight: 356.42  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



## Biological Description

Description	QNZ (EVP4593) (EVP4593) is an effective inhibitor of NF-κB activation and TNF-α production. The IC <sub>50</sub> of QNZ for NF-κB and TNF-α is 11 nM and 7 nM, respectively.
Targets(IC <sub>50</sub> )	NF-κB, TNF
In vitro	Intraperitoneal injection of EVP4593 (1 mg/kg) in rats suppressed carrageenan-induced paw edema in a dose-dependent manner.
In vivo	In murine spleen cells stimulated by lipopolysaccharide, EVP4593 (IC <sub>50</sub> = nM) inhibits the production of TNF-α. In rat neutrophils, EVP4593 (10 nM) suppresses the upregulation of CSE expression induced by lipopolysaccharide. EVP4593 (40 nM) entirely inhibits the increase in the number and length of axons during laminin treatment in Schwann cell adhesion. Additionally, in IB4-negative neurons, EVP4593 (100 nM) blocks the induction effect of GRO/KC on K currents.

## Solubility Information

Solubility	Ethanol: < 1 mg/mL (insoluble or slightly soluble), H <sub>2</sub> O: < 1 mg/mL (insoluble or slightly soluble), DMSO: 250 mg/mL (701.42 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.81 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.8057 mL	14.0284 mL	28.0568 mL
5 mM	0.5611 mL	2.8057 mL	5.6114 mL
10 mM	0.2806 mL	1.4028 mL	2.8057 mL
50 mM	0.0561 mL	0.2806 mL	0.5611 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

## Reference

Tobe M, et al. *Bioorg Med Chem*, 2003, 11(3), 383-391.

Lai X, Wang M, Zhu Y, et al. ZnO NPs delay the recovery of psoriasis-like skin lesions through promoting inflammation and keratinocyte apoptosis via nuclear translocation of phosphorylated NF- $\kappa$ B p65 and cysteine deficiency. *Journal of Hazardous Materials*. 2020: 124566

Hu Q, Du H, Ma G, et al. Purification, identification and functional characterization of an immunomodulatory protein from *Pleurotus eryngii*. *Food & Function*. 2018, 9(7): 3764-3775

VA Vigont, et al. *Biochemistry (Mosc)*, 2012, 6(2), 206-214.

Armstrong SJ, et al. *Neurosci Lett*, 2008, 439(1), 42-46.

Zhang R, Tang L, Wang Y, et al. A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy. *Advanced Science*. 2023: 2300116.

Li L, et al. *J Cell Mol Med*, 2009, 13(8B), 2684-2692.

Tan Z, Pan K, Sun M, et al. CCKBR+ cancer cells contribute to the intratumor heterogeneity of gastric cancer and confer sensitivity to FOXO inhibition. *Cell Death & Differentiation*. 2024: 1-16.

He Q, Zhang Y, Li W, et al. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. *Cancer Letters*. 2024: 217214.

Yang RH, et al. *Mol Pain*, 2009, 28(5), 26.

Lai X, Wang M, Zhu Y, et al. ZnO NPs delay the recovery of psoriasis-like skin lesions through promoting inflammation and keratinocyte apoptosis via nuclear translocation of phosphorylated NF- $\kappa$ B p65 and cysteine deficiency[J]. *Journal of Hazardous Materials*. 2020: 124566.

Cao T, Li A Q, Zhang Y, et al. Norwogonin attenuates LPS-induced acute lung injury through inhibiting Src/AKT1/NF- $\kappa$ B signaling pathway. *Phytomedicine*. 2025: 156432.

Wu J, et al. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. *J Neurosci*. 2016 Jan 6;36(1):125-41.

Hu, Qihui, Hengjun Du, Gaoxing Ma, Fei Pei, Ning Ma, Biao Yuan, Paul A. Nakata, and Wenjian Yang. Purification, identification and functional characterization of an immunomodulatory protein from *Pleurotus eryngii* [J]. *Food Funct*. 2018 Jul 17;9(7):3764-3775.

Lai X, Wang M, Zhu Y, et al. ZnO NPs delay the recovery of psoriasis-like skin lesions through promoting inflammation and keratinocyte apoptosis via nuclear translocation of phosphorylated NF- $\kappa$ B p65 and cysteine deficiency[J]. *Journal of Hazardous Materials*. 2020: 124566.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481